JAMA published study showing US menopause hormone therapy dispensing more than doubled since 2023.
Researchers reported November 19 in JAMA that monthly menopause hormone therapy dispensing for US women aged 40-74 grew from 2 million to 4.9 million since 2023.
The American Skin Association announced 13 total recipients for its 2026 dermatology research grant program. Dispensing rates for this age group increased from 28 prescriptions per 1000 women to 67 prescriptions per 1000 women over the study period. The increase in hormone therapy use began in 2024, continued through 2025, and persisted into 2026 after the FDA removed the therapy's black box warning.
Sun Pharma contributed $300,000 to fund three 2026 Investigative Scientist Awards under the ASA grant program. The 2026 grant cycle expands supported research to include hidradenitis suppurativa, systemic mastocytosis, and dermatologic uses of anti-obesity medications. Dana Sarnak of Johns Hopkins School of Medicine stated that greater women's health attention, updated guidance, and social media may be driving increased interest.
American Skin Association Chairman Howard P. Milstein stated the grant program advances the organization's mission to improve patient outcomes for skin disease.
Read with its sources →